Fig. 3: COVID-19 risk by D35 antibody marker level in baseline SARS-CoV-2 negative per-protocol vaccine recipients (U.S. study sites).
From: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Baseline risk score-adjusted cumulative incidence of COVID-19 by Low, Medium, High tertile of D35 antibody marker level. a, d Anti-spike IgG concentration; b, d anti-RBD IgG concentration; c, d pseudovirus (PsV) nAb-ID50 titer, where in c the estimate for the High tertile is very similar to that for the Medium tertile and hence appears superimposed with the Medium tertile estimate. No p values for hypothesis tests are used because of the small number of COVID-19 breakthrough cases, as specified in the Statistical Analysis Plan. Source data are provided in Fig. 3 Source Data file. D35, Day 35 visit; ID50, 50% inhibitory dilution; nAb neutralizing antibody; RBD receptor binding domain.
